Rohto Pharma (India) Profile
Key Indicators
- Authorised Capital ₹ 117.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 116.50 Cr
as on 16-11-2024
- Company Age 14 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -96.33%
(FY 2023)
- Profit 81.17%
(FY 2023)
- Ebitda 83.17%
(FY 2023)
- Net Worth -230.49%
(FY 2023)
- Total Assets -67.36%
(FY 2023)
About Rohto Pharma (India)
The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 117.00 Cr and a paid-up capital of Rs 116.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Rohto Pharma (India) Private Limited India is Supreet Rekhi as COMPANY SECRETARY. Keiji Nakajima, Koji Suzuki, and Daiki Kato serve as directors at the Company.
- CIN/LLPIN
U24100HR2010FTC053292
- Company No.
053292
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
23 Sep 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Gurugram, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Rohto Pharma (India) Private Limited offer?
Rohto Pharma (India) Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, HIV Drugs, Cosmetics, Hair & Beauty Products, Lip Cosmetics, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs.
Who are the key members and board of directors at Rohto Pharma (India)?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Koji Suzuki  | Managing Director | 23-Sep-2010 | Current |
Supreet Rekhi  | Company Secretary | 26-Mar-2024 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Keiji Nakajima | Director | 01-Apr-2021 | Current |
| Daiki Kato | Director | 05-Aug-2020 | Current |
Financial Performance and Corporate Structure Insights of Rohto Pharma (India).
Rohto Pharma (India) Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 96.33% decrease. The company also saw a substantial improvement in profitability, with a 81.17% increase in profit. The company's net worth observed a substantial decline by a decrease of 230.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rohto Pharma (India)?
In 2023, Rohto Pharma (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Misaki Plastic Technologies Private LimitedActive 15 years 4 monthsKeiji Nakajima is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rohto Pharma (India)?
Rohto Pharma (India) has a workforce of 34 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rohto Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rohto Pharma (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
